Showing 1691-1700 of 2526 results for "".
- Study: Glaucoma Monitoring Lags in Low-Income and Rural Areashttps://modernod.com/news/study-glaucoma-monitoring-lags-in-low-income-and-rural-areas/2482710/A new Northwestern University study suggests that race, income and where patients live play a major role in the level of care glaucoma patients receive. Researchers found that Black, Hispanic and Asian American patients, as well as those from rural and economically distressed communities, are sig
- Sydnexis Announces FDA Acceptance of NDA for SYD-101 for the Treatment of Progression of Pediatric Myopiahttps://modernod.com/news/sydnexis-announces-fda-acceptance-of-nda-for-syd-101-for-the-treatment-of-progression-of-pediatric-myopia/2482697/Sydnexis announced that the FDA has accepted its new drug application (NDA) for SYD-101, which if approved would be the first and only pharmaceutical option for the treatment of progression of pediatric myopia in the United States. The FDA assigned a Prescription Drug Use
- Latinos En Optometry and VSP Vision Launch New Series Focused on Enhancing Cultural Competencyhttps://modernod.com/news/latinos-en-optometry-and-vsp-vision-launch-new-series-focused-on-enhancing-cultural-competency/2482689/Latinos en Optometry has collaborated with VSP Vision to launch a new blog series called “Cultural Responsiveness.” The initiative seeks to support both existing and prospective practitioners in understanding the importance of healthcare services that are responsive to the s
- Formycon Receives Approval in the UK for Eylea Biosimilarhttps://modernod.com/news/formycon-receives-approval-in-the-uk-for-eylea-biosimilar/2482680/Formycon and its licensing partner Klinge Biopharma jointly announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved FYB203 (aflibercept), a biosimilar to Eylea (Regeneron), under the brand name Ahzantine. The approval covers the treatment
- World’s First AI-Powered Cardiovascular Retinal Screening to be Launched in the UKhttps://modernod.com/news/worlds-first-ai-powered-cardiovascular-retinal-screening-to-be-launched-in-the-uk/2482674/Heart Eye has unveiled AI-powered cardiovascular screening technology using retinal imaging in the UK. The company says the technology delivers patients’ cardiovascular disease risk results in just 3 minutes. The technology, called '
- Cost, Purchase Factors, and Correct Usage Drive Online Contact Lens Searcheshttps://modernod.com/news/cost-purchase-factors-and-correct-usage-drive-online-contact-lens-searches-according-to-new-research-in-the-us-and-canada/2482671/New research from the Contact Lens Institute (CLI) demonstrates that purchase factors–specificly contact lens retailers and price–are the primary driver of consumer online contact lens-related searches, representing 65% of top 20 searches in the United States and Canada. Oth
- Rayner Completes Recruitment for RayOne Galaxy IDE Studyhttps://modernod.com/news/rayner-completes-recruitment-for-rayone-galaxy-ide-study/2482642/Rayner announced the closure of recruitment in the Investigational Device Exemption (IDE) study for the RayOne Galaxy IOL in the United States. Developed in collaboration with Brazilian ophthalmologist João Lyra, MD, PhD, RayOne Galaxy is the worl
- Outlook Therapeutics Presents Results from NORSE EIGHT Trial Evaluating ONS-5010 for the Treatment of Wet AMDhttps://modernod.com/news/outlook-therapeutics-presents-efficacy-and-safety-results-from-norse-eight-trial-evaluating-ons-5010-for-the-treatment-of-wet-amd/2482632/Outlook Therapeutics announced the presentation of data from NORSE EIGHT at the Hawaiian Eye and Retina 2025 Meeting. Baruch D. Kuppermann, MD, PhD, of Gavin Herbert Eye Institute, University of California, Irvine, CA presented the abstract titled, “ONS-5010 (bevacizumab-vikg
- Heidelberg Hosts First International Glaucoma Symposiumhttps://modernod.com/news/heidelberg-hosts-first-international-glaucoma-symposium/2482628/The first International Glaucoma Symposium will be held by Heidelberg Engineering in conjunction with Mainz University on February 1, 2025. Bringing together specialists from around the world, the symposium calls for AI to be fully implemented as an increasing number of glaucoma and dia
- HelpMeSee Expands Simulation-based Cataract Surgery Training with New Partnerships at USC and UIChttps://modernod.com/news/helpmesee-expands-simulation-based-cataract-surgery-training-with-new-partnerships-at-usc-and-uic/2482623/HelpMeSee has announce its latest training partnerships with the University of Southern (USC)/LA General Medical Center in Los Angeles, and the University of Illinois Chicago (UIC). These collaborations establish two new